Carmustine
- Generic Name
- Carmustine
- Brand Names
- Bicnu, Gliadel, Carmustine medac (previously Carmustine Obvius)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H9Cl2N3O2
- CAS Number
- 154-93-8
- Unique Ingredient Identifier
- U68WG3173Y
Overview
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Background
A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed)
Indication
For the treatment of brain tumors, multiple myeloma, Hodgkin's disease and Non-Hodgkin's lymphomas.
Associated Conditions
- Astrocytoma
- Brain Stem Gliomas
- Ependymoma
- High Grade Glioma: Glioblastoma (GBM)
- Medulloblastomas
- Metastatic Brain Tumors
- Mycosis Fungoides (MF)
- Newly Diagnosed High-Grade Glioma
- Recurrent Glioblastoma Multiforme (GBM)
- Refractory Hodgkin Lymphoma
- Refractory Multiple Myeloma
- Refractory Non-Hodgkin's lymphoma
Clinical Trials
FDA Approved Products
Singapore Approved Products
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.